2025 annual financial data
Sarepta Therapeutics 2025 Operating cash flow margin
Direct answer
Operating cash flow margin was -9.35%.
Operating income was -657,772,000 USD and net income was -713,410,000 USD.
Operating cash flow was -205,479,000 USD.
Get free Sarepta Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,198,237,000 USD
- Operating income
- -657,772,000 USD
- Net income
- -713,410,000 USD
- Operating cash flow
- -205,479,000 USD